Analyst Reco.

04-16 Telix Enters Attractive Market With Late-Stage Brain Cancer Drug Trial in US, Jefferies Says MT
04-13 Telix Pharmaceuticals' Pipeline Validated by Regeneron Deal, Citi Says MT
04-08 Jarden Adjusts Telix Pharmaceuticals's Price Target to AU$21.80 from AU$21, Keeps at Buy MT
04-07 Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies MT
01-21 Telix Pharmaceuticals Poised for Growth With Strong Illuccix Sales, Gozellix Launch, Jefferies Says MT
01-13 Telix Pharmaceuticals Reaffirms Guidance Amid Imminent Drug Launches in US, Says Jefferies MT
12-11 Telix Pharmaceuticals Poised for 'Solid' Q4 Revenue Growth, Jefferies Says MT
11-12 Alerts from law firm on Telix pharmaceuticals withdrawn RE
11-12 Telix Reports Positive Results from TLX250-CDx Imaging Trial in Triple Negative Breast Cancer Patients, Shares Fall 3% MT
07/10/25 Barrenjoey Markets Starts Telix Pharmaceuticals at Overweight with AU$22 Price Target MT
25/09/25 Telix Pharmaceuticals' Gozellix Expected to See Strong Sales Growth After TPT Status Grant, Jarden Research Says MT
23/09/25 UBS Adjusts Price Target on Telix Pharmaceuticals to $20 From $23, Maintains Buy Rating MT
19/09/25 Telix Pharmaceuticals Shows Strong Growth Potential With Blockbuster Drug Prospect, Citi Says MT
18/09/25 Citigroup Initiates Telix Pharmaceuticals at Buy With $22 Price Target MT
21/08/25 Telix Pharmaceuticals' Profitability Expected to Rebound, Wedbush Says MT
06/08/25 Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy MT
03/07/25 HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target MT
05/06/25 Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target MT
27/01/25 UBS Adjusts Price Target on Telix Pharmaceuticals to $22 From $21, Keeps Buy Rating MT
30/09/24 Telix Pharmaceuticals Has Long-term Opportunity to Become Isotope Manufacturer After Acquisition, Says Jefferies MT
23/08/24 Bell Potter Downgrades Telix Pharmaceuticals to Hold From Buy; Price Target is AU$21.30 MT
30/07/24 Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$22.55 From AU$22.49, Keeps at Buy MT
03/06/24 Jarden Research Adjusts Telix Pharmaceuticals’ Price Target to AU$16.62 From AU$13.94, Keeps at Buy MT
30/04/24 Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50 MT
18/04/24 Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy MT
No results match your criteria
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!